These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32133329)

  • 1. Palliative Care in SMA Type 1: A Prospective Multicenter French Study Based on Parents' Reports.
    Hully M; Barnerias C; Chabalier D; Le Guen S; Germa V; Deladriere E; Vanhulle C; Cuisset JM; Chabrol B; Cances C; Vuillerot C; Espil C; Mayer M; Nougues MC; Sabouraud P; Lefranc J; Laugel V; Rivier F; Louvier UW; Durigneux J; Napuri S; Sarret C; Renouil M; Masurel A; Viallard ML; Desguerre I
    Front Pediatr; 2020; 8():4. PubMed ID: 32133329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Multicentric study of medical care and practices in spinal muscular atrophy type 1 over two 10-year periods].
    Barnérias C; Quijano S; Mayer M; Estournet B; Cuisset JM; Sukno S; Peudenier S; Laroche C; Chabrier S; Sabouraud P; Vuillerot C; Chabrol B; Halbert C; Cancès C; Beze-Beyrie P; Ledivenah A; Viallard ML; Desguerre I
    Arch Pediatr; 2014 Apr; 21(4):347-54. PubMed ID: 24630620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: a longitudinal qualitative study.
    Kiefer P; Kirschner J; Pechmann A; Langer T
    Orphanet J Rare Dis; 2020 Jul; 15(1):194. PubMed ID: 32727502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
    Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
    J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do we always need to treat patients with spinal muscular atrophy? A personal view and experience.
    Agosto C; Salamon E; Divisic A; Benedetti F; Giacomelli L; Shah A; Perilongo G; Benini F
    Orphanet J Rare Dis; 2021 Feb; 16(1):78. PubMed ID: 33573692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare utilisation in children with SMA type 1 treated with nusinersen: a single centre retrospective review.
    Ali I; Gilchrist FJ; Carroll WD; Alexander J; Clayton S; Kulshrestha R; Willis T; Samuels M
    BMJ Paediatr Open; 2019; 3(1):e000572. PubMed ID: 31909224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
    Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
    J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world respiratory and bulbar comorbidities of SMA type 1 children treated with nusinersen: 2-Year single centre Australian experience.
    Chen KA; Widger J; Teng A; Fitzgerald DA; D'Silva A; Farrar M
    Paediatr Respir Rev; 2021 Sep; 39():54-60. PubMed ID: 33129670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nusinersen for SMA: expanded access programme.
    Farrar MA; Teoh HL; Carey KA; Cairns A; Forbes R; Herbert K; Holland S; Jones KJ; Menezes MP; Morrison M; Munro K; Villano D; Webster R; Woodcock IR; Yiu EM; Sampaio H; Ryan MM
    J Neurol Neurosurg Psychiatry; 2018 Sep; 89(9):937-942. PubMed ID: 29549190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nusinersen for the treatment of spinal muscular atrophy.
    Chiriboga CA
    Expert Rev Neurother; 2017 Oct; 17(10):955-962. PubMed ID: 28884620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives on Spinraza (Nusinersen) Treatment Study: Views of Individuals and Parents of Children Diagnosed with Spinal Muscular Atrophy.
    Pacione M; Siskind CE; Day JW; Tabor HK
    J Neuromuscul Dis; 2019; 6(1):119-131. PubMed ID: 30594933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spinal muscular atrophy: survival pattern and functional status.
    Chung BH; Wong VC; Ip P
    Pediatrics; 2004 Nov; 114(5):e548-53. PubMed ID: 15492357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
    Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM
    Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy.
    Pechmann A; König K; Bernert G; Schachtrup K; Schara U; Schorling D; Schwersenz I; Stein S; Tassoni A; Vogt S; Walter MC; Lochmüller H; Kirschner J
    Orphanet J Rare Dis; 2019 Jan; 14(1):18. PubMed ID: 30665421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Areas of improvement in the medical care of SMA: evidence from a nationwide patient registry in Germany.
    Leibrock B; Landfeldt E; Hussong J; Huelle T; Mattheus H; Thiele S; Walter MC; Zemlin M; Moehler E; Dillman U; Abner S; Flotats-Bastardas M
    Orphanet J Rare Dis; 2023 Feb; 18(1):32. PubMed ID: 36810103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing respiratory expectations with the new disease trajectory of nusinersen treated spinal muscular atrophy [SMA] type 1.
    Fitzgerald DA; Doumit M; Abel F
    Paediatr Respir Rev; 2018 Sep; 28():11-17. PubMed ID: 30414815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spinal muscular atrophy: epidemiology and health burden in children - a Polish national healthcare database perspective before introduction of SMA-specific treatment.
    Kostera-Pruszczyk A; Napiórkowski Ł; Szymańska K; Jędrzejczak J; Roszkowski M; Słowiński J; Frączek A; Ryglewicz D; Więckowska B
    Neurol Neurochir Pol; 2021; 55(5):479-484. PubMed ID: 34664710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palliative care in children with spinal muscular atrophy type I: What do they need?
    García-Salido A; de Paso-Mora MG; Monleón-Luque M; Martino-Alba R
    Palliat Support Care; 2015 Apr; 13(2):313-7. PubMed ID: 24565112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive institutional overview of intrathecal nusinersen injections for spinal muscular atrophy.
    Mousa MA; Aria DJ; Schaefer CM; Kaye RD; Abruzzo TA; Bernes SM; Willard SD; Riemann MC; Towbin RB
    Pediatr Radiol; 2018 Nov; 48(12):1797-1805. PubMed ID: 30022258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.